Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 + Gem/Nab-P in Advanced Pancreatic Cancer
NCT04624217Phase 2Completed
- Sponsor
- Hengrui
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in pancreatic cancer (PC), sponsored by Hengrui. Primary endpoints: Recommended Phase 2 Dose and Objective Response Rate up to 6 months. Started Nov 2020; status: completed.
02
Drugs
retlirafusp alfa
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04624217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624217.